Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2017 07:01 ET | Source: Agios Pharmaceuticals

Agios Reports First Quarter 2017 Financial Results

– IDHIFA® (enasidenib) Granted Priority Review by FDA with August 30, 2017 PDUFA Date; Updated Data from Phase 1/2 Trial in IDH2m R/R AML to be Presented at ASCO – – Ivosidenib Phase 1 125-Patient...
April 28, 2017 16:01 ET | Source: Agios Pharmaceuticals

Agios Announces Closing of Over-Allotment Option in Public Offering

CAMBRIDGE, Mass., April 28, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it has issued an additional 757,575 shares of common stock at the public offering...
April 27, 2017 07:30 ET | Source: Agios Pharmaceuticals

Agios and Aurigene Enter into Exclusive License Agreement for Novel Small Molecules for Cancer Metabolism Target

CAMBRIDGE, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) and Aurigene Discovery Technologies Limited today announced a global license agreement to research,...
April 27, 2017 07:25 ET | Source: Agios Pharmaceuticals

Agios to Webcast Conference Call of First Quarter 2017 Financial Results on May 4, 2017

CAMBRIDGE, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...
April 26, 2017 07:01 ET | Source: Agios Pharmaceuticals

Agios Announces Exercise of Over-Allotment Option in Public Offering

CAMBRIDGE, Mass., April 26, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that the underwriters of its previously announced public offering of common stock have...
April 24, 2017 16:01 ET | Source: Agios Pharmaceuticals

Agios Announces Closing of Public Offering

CAMBRIDGE, Mass., April 24, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced the closing of its previously announced underwritten public offering of 5,050,505...
April 18, 2017 20:34 ET | Source: Agios Pharmaceuticals

Agios Announces Pricing of $250 Million Public Offering of Common Stock

CAMBRIDGE, Mass., April 18, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it has priced an underwritten a public offering of 5,050,505 shares of common...
April 17, 2017 16:01 ET | Source: Agios Pharmaceuticals

Agios Announces Proposed Offering of Common Stock

CAMBRIDGE, Mass., April 17, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it is offering to sell, subject to market and other conditions, up to 4.5 million...
March 30, 2017 07:30 ET | Source: Agios Pharmaceuticals

Agios to Present at the 16th Annual Needham Healthcare Conference on Tuesday April 4, 2017

CAMBRIDGE, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...
March 13, 2017 07:30 ET | Source: Agios Pharmaceuticals

Agios Announces MTAP Pathway Research Program as Development Program and Development Candidate Under Master Research and Collaboration Agreement with Celgene

CAMBRIDGE, Mass., March 13, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced that Celgene Corporation has designated the development candidate focused on MTAP...